ArticleImmunity, inflammation and disease2026
The Bufei Nashen Pill Alleviates COPD by Targeting Endoplasmic Reticulum Stress Through the PERK/eIF2α Signaling Pathway.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GRP78 in human diseases: From molecular chaperone to therapeutic target.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEvidence supporting the therapeutic efficacy of Bufei Nashen pill (BFNSP) for chronic obstructive pulmonary disease (COPD) is currently limited. We evaluated BFNSP's effects on COPD progression and elucidated its potential mechanisms through LC/MS analysis of its active components.
methodsFollowing the establishment of a rat COPD model, animals received graded BFNSP doses. Pulmonary function testing quantified respiratory parameters, while HE staining revealed histological changes in lung tissue. ELISA was used to measure TGF-β1, IL-6, IL-8, and IL-1β concentrations in BALF, as well as MDA, SOD, and GSH levels in lung tissue. Immunofluorescence staining was used to detect the levels of GRP78 and CHOP expression. Protein expression levels of GRP78, CHOP, p-PERK, p-eIF2α, and p-ATF4 in lung tissue were analyzed using Western blotting. The results were further confirmed through in vitro cellular assays.
resultsThe study found that BFNSP improved pulmonary ventilation, reduced lung tissue damage, decreased inflammatory factor secretion, and alleviated oxidative and endoplasmic reticulum stress in COPD rats by inhibiting the PERK/eIF2α signaling pathway, potentially slowing COPD progression.
conclusionBFNSP mitigates COPD progression by regulating endoplasmic reticulum stress via the suppression of the PERK/eIF2α signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.